Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02508038
Other study ID # UW13090
Secondary ID NCI-2015-0116320
Status Recruiting
Phase Phase 1
First received
Last updated
Start date February 12, 2016
Est. completion date December 2025

Study information

Verified date November 2023
Source University of Wisconsin, Madison
Contact Jenny Weiland
Phone 608-890-8070
Email PedsHemOncResearch@g-groups.wisc.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase I trial studies the safety of transplantation with a haploidentical donor peripheral blood stem cell graft depleted of TCRαβ+ cells and CD19+ cells in conjunction with the immunomodulating drug, Zoledronate, given in the post-transplant period to treat pediatric patients with relapsed or refractory hematologic malignancies or high risk solid tumors.


Description:

CONDITIONING REGIMENS: Patients with high-risk leukemia will receive myeloablative conditioning with anti-thymocyte globulin intravenously (IV) over 4-6 hours on days -12 through -9, Fludarabine IV over 30 minutes on days -8 through -5, Thiotepa IV every every 12 hours on day -4 and Total Body Irradiation (TBI) on days -3 through -1. All other patients receive reduced intensity conditioning consisting of anti-thymocyte globulin intravenously (IV) over 4-6 hours on days -12 through -9, fludarabine IV over 30 minutes on days -8 through -5, thiotepa IV over 4 hours every 12 hours on day -4, and melphalan IV on days -3 and -2. PERIPHERAL BLOOD STEM CELL TRANSPLANTATION: Patients undergo TCR-alpha/beta+ and CD19+ depleted KIR/KIR ligand-mismatched haploidentical donor peripheral blood stem cell transplantation on day 0. If the graft contains less than 4 x 10^6 CD34+ cells/kg, a second HSC graft may be administered. PROPHYLAXIS FOR GVHD: Patients receiving a graft containing > 25 x 10^3 CD3+ TCR alpha/beta+ cells receive mycophenolate mofetil IV twice daily over 2 hours on days 1 to 30 with a rapid taper. Patients with TCR alpha/beta+ cells exceeding 100,000/kg also receive tacrolimus IV continuously or orally (PO) every 12 hours on days 0-90 with a taper at the discretion of the Principal Investigator. ZOLEDRONATE ADMINISTRATION: Patients will receive five doses of Zoledronate (IV) at 28 day intervals beginning on Day +28 post-HSCT. Follow-up assessments will occur after transplantation.


Recruitment information / eligibility

Status Recruiting
Enrollment 22
Est. completion date December 2025
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 7 Months to 21 Years
Eligibility Inclusion Criteria: - Availability of an eligible haploidentical donor - Hematologic malignancy or solid tumor - Patients with more than one malignancy (hematologic or solid tumor) are eligible - Patients with hematologic malignancy must have no HLA identical sibling or suitable unrelated donor OR time needed to find an acceptable unrelated donor match would likely result in disease progression such that the patient may become ineligible for any type of potentially curative transplant - Relapsed or primary therapy-refractory AML with bone marrow blast < 20% - High-risk refractory or relapsed ALL in patients for whom transplantation is deemed indicated (relapse occurring < 30 months from diagnosis, patients relapsing after previous allogeneic transplant, relapse after 2nd remission, primary induction failure or hypodiploidy) - Relapsed Hodgkin lymphoma unable to achieve 2nd remission or Very Good Partial Response (VGPR) and therefore ineligible to receive autologous hematopoietic stem cell transplant (auto-HSCT) - Hodgkin lymphoma relapsing after auto-HSCT - Primary refractory or relapsed non-Hodgkin lymphoma unable to achieve 2nd remission or VGPR and therefore ineligible to receive auto-HSCT - Non-Hodgkin lymphoma relapsing after auto-HSCT - Myelodysplastic Syndrome/Myeloproliferative Syndrome Solid Tumor - Patients with solid tumor must have failed or have been ineligible to receive auto-HSCT or if auto-HSCT would not offer > 20% chance of cure - Neuroblastoma - high risk with relapsed or refractory disease - Soft tissue sarcomas (Rhabdomyosarcoma, Ewing sarcoma, Primitive Neuroectodermal Tumor or other high-risk extracranial solid tumors) - Relapsed or primary refractory metastatic - 1st complete remission, but very high-risk features (i.e., < 20% survival with conventional therapy) - Osteosarcoma - Failure to achieve Complete Response (CR) following initial therapy - Relapsed with pulmonary or bone metastases and did not achieve a CR with surgery and/or chemotherapy - Karnofsky (patients > 16 years) or Lansky (patients 16 years or older) performance score of = 60 - Life expectancy of = 3 months - Patient must have fully recovered from acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study - Study enrollment no earlier than 3 months after preceding HSCT - Glomerular Filtration Rate (GFR) = 60 ml/min/1.73m2 - Total bilirubin < 3 mg/dL - ALT (alanine aminotransferase, SCPT) = 5 x Upper LImit of Normal (ULN) for age - Ejection fraction of > 40% by Multigated Acquisition Scan (MUGA) or echocardiogram - No evidence of dyspnea at rest - No supplemental oxygen requirement - If measured, carbon monoxide diffusion capacity (DLCO) >50% - No severe peripheral neuropathy, signs of leukoencephalopathy or active Central Nervous System (CNS) infection - Patients with seizure disorders may be enrolled if seizures are well controlled on anticonvulsant therapy - If of reproductive potential, negative pregnancy test and willing to use effective birth control method - Informed consent from patient or legal guardian (if patient is minor) Inclusion Criteria for Donors: - Donor must be 18 years of age minimum, 65 years of age maximum - Donor must be in good general health as determined by evaluating medical provider - Must meet donor criteria for human cells, tissues, and cellular and tissue-based products per Code of Federal Regulations 21 CFR 1271, subpart C. Specifically: - Donor screening in accordance with 1271.75 indicates that the donor: - Is free from risk factors for, and clinical evidence of, infection due to relevant communicable disease agents and diseases; and - Is free from communicable disease risks associated with xenotransplantation; and - The results of donor testing for relevant communicable disease agents in accordance with 1271.80 and 1271.85 are negative or nonreactive, except as provided in 1271.80(d)(1). - Haploidentical by HLA-typing - Preference will be given to donors who demonstrate KIR incompatibility with recipient HLA class I ligands defined as the donor expressing a KIR gene for which the corresponding HLA class I ligand is not expressed by the recipient. - Negative testing for relevant communicable diseases: - Hepatitis B surface antigen (HBsAg) - Hepatitis B core antibody (Anti-HBc) - Hepatitis C antibody (Anti-HCV) - HIV 1 & 2 antibody (Anti-HIV-1, 2 plus O) - HTLV I/II antibody (Anti-HTLV I/II) - RPR (Syphilis TP) - CMV (Capture CMV) - MPX for: HepB (HBV-PCR), HepC (HCV-PCR), HIV (HIV-PCR) - NAT for West Nile Virus (WNV-PCR) - T. Cruzi - EIA (Chagas) Exclusion Criteria: - Pregnant or breast-feeding - HIV infection - Heart failure or uncontrolled cardiac rhythm disturbance - Uncontrolled, Serious Active Infection - Prior organ allograft - Significant serious intercurrent illness unrelated to cancer or its treatment not covered by other exclusion criteria expected to significantly increase the risk of HSCT - Any mental or physical condition, in the opinion of the PI (or PI designee), which could interfere with the ability of the subject (or the only parent or legal guardian available to care for the subject) to understand or adhere to the requirements of the study - Enrollment in any other clinical study from screening up to Day 100 (unless PI judges such enrollment would not interfere with endpoints of this study) Exclusion Criteria for Donors: - Lactating females - Pregnant females

Study Design


Intervention

Procedure:
TCRaß+/CD19+ depleted Haploidentical HSCT
Patients with high-risk leukemia will receive myeloablative conditioning. All other patients will undergo a reduced-intensity conditioning with ATG, Fludarabine, Thiotepa and Melphalan followed by transplant with a KIR/KIR (Killer cell immunoglobulin-like recetptor) ligand mismatched haploidentical donor peripheral blood stem cell graft depleted of TCRab+ cells and CD19+ cells using the CliniMACS System.
Drug:
Zoledronate
Given IV. Patients will receive five doses of Zoledronate (each 1.25 mg/m2 at a 28 day interval) following transplant.

Locations

Country Name City State
United States University of Wisconsin Carbone Cancer Center Madison Wisconsin

Sponsors (1)

Lead Sponsor Collaborator
University of Wisconsin, Madison

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of acute graft versus host disease (GVHD) Within 100 days post-transplantation
Primary Incidence of graft failure At day 28
Secondary Immune reconstitution Immune reconstitution outcomes, as determined by immune cell analysis. Up to 1 year
Secondary Performance of the CliniMACS Reagent System utilizing the CliniMACS TCRaß-biotin and CliniMACS CD19 reagent to produce a graft with defined cell content. The performance of the CliniMACS Reagent System will be evaluated by measuring the number of viable stem cells, TCRaß+ cells, TCR?d+ cells, NK cells and B cells in the hematopoietic stem cell graft. Day 0
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Recruiting NCT04460235 - Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma Phase 4
Completed NCT04022785 - PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Phase 1
Completed NCT03678493 - A Study of FMT in Patients With AML Allo HSCT in Recipients Phase 2
Recruiting NCT05424562 - A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
Completed NCT03197714 - Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia Phase 1
Terminated NCT03224819 - Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) Early Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Active, not recruiting NCT04070768 - Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113 Phase 1
Active, not recruiting NCT04107727 - Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML) Phase 2
Recruiting NCT04385290 - Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) Phase 1/Phase 2
Recruiting NCT04920500 - Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients N/A
Recruiting NCT03897127 - Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics Phase 3
Active, not recruiting NCT04021368 - RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Phase 1
Recruiting NCT03665480 - The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML Phase 2/Phase 3
Completed NCT02485535 - Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant Phase 1
Enrolling by invitation NCT04093570 - A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers Phase 2
Recruiting NCT04069208 - IA14 Induction in Young Acute Myeloid Leukemia Phase 2
Recruiting NCT05744739 - Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML) Phase 1
Recruiting NCT04969601 - Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings Phase 1/Phase 2